• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/5/21 4:48:17 PM ET
    $MSON
    Medical Specialities
    Capital Goods
    Get the next $MSON alert in real time by email
    SC 13G/A 1 ea134706-13ga11315cap_miso.htm AMENDMENT NO. 1 TO SCHEDULE 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 1)*

     

    Misonix, Inc.

    (Name of Issuer)

     

    Common Shares, $0.0001 par value

    (Title of Class of Securities)

     

    604871103

    (CUSIP Number)

     

    December 31, 2020

    (Date of Event which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ☐ Rule 13d-1(b)

     

    ☒ Rule 13d-1(c)

     

    ☐ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

     

    CUSIP No. 604871103  

     

    1 Names of Reporting Persons
    1315 Capital, L.P.
    2 Check the appropriate box if a member of a Group (see instructions)

    (a) ☐

    (b) ☐

    3 SEC Use Only
     
    4 Citizenship or Place of Organization
    Delaware

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting
    Person With:

     

    5 Sole Voting Power
    0
    6 Shared Voting Power
    1,694,017
    7 Sole Dispositive Power
    0
    8 Shared Dispositive Power
    1,694,017
    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    1,694,017
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    ☐
    11 Percent of class represented by amount in row (9)
    9.7%
    12 Type of Reporting Person (See Instructions)
    PN
           

    2

     

     

    CUSIP No. 604871103  

     

    1 Names of Reporting Persons
    1315 Capital Management, LLC
    2 Check the appropriate box if a member of a Group (see instructions)

    (a) ☐

    (b) ☐

    3 SEC Use Only
     
    4 Citizenship or Place of Organization
    Delaware

    Number of
    Shares
    Beneficially
    Owned by Each
    Reporting
    Person With:

     

    5 Sole Voting Power
    0
    6 Shared Voting Power
    1,694,017
    7 Sole Dispositive Power
    0
    8 Shared Dispositive Power
    1,694,017
    9 Aggregate Amount Beneficially Owned by Each Reporting Person
    1,694,017
    10 Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)
    ☐
    11 Percent of class represented by amount in row (9)
    9.7%
    12 Type of Reporting Person (See Instructions)
    OO
           

    3

     

     

    Item 1.

     

    (a) Name of Issuer: Misonix, Inc.

     

    (b) Address of Issuer’s Principal Executive Offices: 1938 New Highway, Farmingdale, New York 11735

     

    Item 2.

     

    (a)Name of Person Filing: This statement is filed by: (i) 1315 Capital, L.P., a Delaware limited partnership and (ii) 1315 Capital Management, LLC, a Delaware limited liability company and general partner of 1315 Capital, L.P. 1315 Capital, L.P. and 1315 Capital Management, LLC are sometimes referred to collectively as the “Reporting Persons.”
      
    (b)Address of Principal Business Office or, if None, Residence: The principal place of business of the Reporting Persons is c/o 1315 Capital, 2929 Walnut Street, Suite 1240, Philadelphia, PA 19104.

     

    2929 Walnut Street, Suite 1240

     

    Philadelphia, PA 19104

     

    (c)Citizenship: Each of the Reporting Persons are organized under the laws of the State of Delaware.
      
    (d)Title and Class of Securities: Common Shares, par value $0.0001 (the “Shares”)
      
    (e)CUSIP No.: 604871103

     

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     

    (a)  ☐Broker or dealer registered under Section 15 of the Act;
    (b)  ☐Bank as defined in Section 3(a)(6) of the Act;
    (c)  ☐Insurance company as defined in Section 3(a)(19) of the Act;
    (d)  ☐Investment company registered under Section 8 of the Investment Company Act of 1940;
    (e)  ☐An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
    (f)  ☐An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);
    (g)  ☐A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
    (h)  ☐A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)  ☐A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940;
    (j)  ☐A non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J);
    (k)  ☐Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____

     

    4

     

     

    Item 4.Ownership

     

    (a)Amount Beneficially Owned:

     

      1315 Capital, L.P.:

    1,694,017 (1)

      1315 Capital Management, LLC:

    1,694,017 (1)

     

    (b) Percent of Class:

     

      1315 Capital, L.P.:

    9.7%

      1315 Capital Management, LLC:

    9.7%

     

    (c) Number of shares as to which such person has:

     

    (i)Sole power to vote or to direct the vote: 0

     

    (ii)Shared power to vote or to direct the vote:

     

      1315 Capital, L.P.:

    1,694,017 (1)

      1315 Capital Management, LLC:

    1,694,017 (1)

     

    (iii)Sole power to dispose or to direct the disposition of: 0

     

    (iv)Shared power to dispose or to direct the disposition of:

     

      1315 Capital, L.P.:

    1,694,017 (1)

      1315 Capital Management, LLC:

    1,694,017 (1)

     

    Item 5.Ownership of Five Percent or Less of a Class.

     

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

     

    Item 6.Ownership of more than Five Percent on Behalf of Another Person. N/A

     

    Item 7.Identification and classification of the subsidiary which acquired the security being reported on by the parent holding company or control person. N/A

     

    Item 8.Identification and classification of members of the group. N/A

     

    Item 9.Notice of Dissolution of Group. N/A

     

    Item 10.Certifications.

     

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

    (1) Acquired pursuant to the Agreement and Plan of Merger between Misonix, Inc., New Misonix, Inc., Motor Reincorp. Sub One, Inc., Surge Sub Two, LLC, Solsys Medical, LLC (“Solsys”), and Greg Madden solely in his capacity as representative, in exchange for 27,116,608 Series E Preferred Units of Solsys. The Merger Agreement placed a value on the issuer’s common stock of $18.5479, which reflects the 10-day VWAP for the issuer’s common stock as of three business days prior to the effective date of the merger. 206,451 of the Shares issued to 1315 Capital, L.P. were held in escrow and were subject to forfeiture during the 15 month-period following the merger to satisfy any post-closing purchase price adjustments and indemnification claims. On January 4, 2021, 1,952 of the Shares held in escrow were forfeited and the remainder were released to 1315 Capital, L.P.

     

    5

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 5, 2021

     

      1315 CAPITAL MANAGEMENT, LLC
         
      By: /s/ Adele C. Oliva
      Name: Adele C. Oliva
      Title: Managing Member
         
      1315 CAPITAL, L.P.
      By: 1315 Capital Management, LLC, its General Partner
         
      By: /s/ Adele C. Oliva
      Name: Adele C. Oliva
      Title: Managing Member

     

     

    6

    Get the next $MSON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MSON

    DatePrice TargetRatingAnalyst
    8/2/2021Buy → Neutral
    BTIG
    7/30/2021$23.00 → $28.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $MSON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Misonix downgraded by BTIG

    BTIG downgraded Misonix from Buy to Neutral

    8/2/21 5:49:45 AM ET
    $MSON
    Medical Specialities
    Capital Goods

    Misonix downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Misonix from Buy to Hold and set a new price target of $28.00 from $23.00 previously

    7/30/21 6:33:04 AM ET
    $MSON
    Medical Specialities
    Capital Goods

    $MSON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bioventus and Misonix Stockholders Approve the Acquisition of Misonix by Bioventus

    DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or the "Company"), a global leader in innovations for active healing, and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine that enhance clinical outcomes, today announced that the stockholders of Bioventus approved the issuance of shares of Bioventus class A common stock to the stockholders of Misonix in connection with the previously announced Agreement and Plan of Merger, dated July 29, 2021, by and among Bioventus, Misonix and other parties thereto, pursuant to which Misonix will be acquired

    10/26/21 4:15:00 PM ET
    $BVS
    $MSON
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Capital Goods

    BIOVENTUS INC. and MISONIX, INC. Announce Election Deadline of 5:00 p.m. New York City Time, on October 25, 2021 for Misonix Stockholders to Elect Form of Merger Consideration

    DURHAM, N.C. and FARMINGDALE, N.Y., Oct. 18, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), today announced an election deadline of 5:00 p.m., New York City Time, on October 25, 2021 (the "Election Deadline") for stockholders of Misonix to elect the form of consideration they wish to receive for their shares of Misonix common stock in connection with the proposed merger of Oyster Merger Sub I, Inc., a newly-formed, wholly-owned subsidiary of Bioventus ("Merger Sub I"), with and into Misonix, immediately followed by the merger of Misonix with and into Oyster Merger Sub II, LLC, another newly-formed, wholly-owned subsidiary of Bioventus ("Me

    10/18/21 8:00:00 AM ET
    $BVS
    $MSON
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Capital Goods

    Misonix Reports Fourth Quarter and Fiscal Year 2021 Financial Results

    FARMINGDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below:  Three Months Ended Years Ended  June 30, June 30,   2021   2020   2021  2020          Revenue$19,685,141  $13,713,231  $74,024,073 $62,483,651  Gross profit$14,075,377  $9,432,383  $52,636,255 $43,709,483  Gross profit percentage 71.5%  68.8%  71.1% 70.0% Pretax loss$(4,341,201) $(8,495,994) $(14,341,254)$(21,91

    9/2/21 4:01:00 PM ET
    $BVS
    $MSON
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Capital Goods

    $MSON
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Koby Michael returned 1,744,017 shares to the company

    4 - MISONIX INC (0000880432) (Issuer)

    12/8/21 5:01:08 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    SEC Form 4: Vizirgianakis Stavros G. returned 2,136,478 shares to the company, closing all direct ownership in the company

    4 - MISONIX INC (0000880432) (Issuer)

    12/8/21 4:56:38 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    SEC Form 4: Patton Thomas M returned 104,500 shares to the company, closing all direct ownership in the company

    4 - MISONIX INC (0000880432) (Issuer)

    12/8/21 4:53:29 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    $MSON
    SEC Filings

    View All

    SEC Form RW filed by MISONIX, Inc.

    RW - MISONIX INC (0000880432) (Filer)

    11/22/21 4:16:00 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    SEC Form 15-12B filed by MISONIX, Inc.

    15-12B - MISONIX INC (0000880432) (Filer)

    11/8/21 4:30:57 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    MISONIX, Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Changes in Control of Registrant, Leadership Update, Financial Statements and Exhibits

    8-K - MISONIX INC (0000880432) (Filer)

    10/29/21 4:50:05 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    $MSON
    Leadership Updates

    Live Leadership Updates

    View All

    Misonix Appoints Patrick J. Beyer to Board of Directors

    FARMINGDALE, N.Y., May 14, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today announced its Board of Directors has appointed Patrick J. Beyer as an independent member of the Board. Mr. Beyer joined the Board on May 12, 2021. "Pat is a highly respected, purpose-driven leader who has a proven, long-term track record of success throughout his career in the healthcare industry," stated Stavros Vizirgianakis, Chief Executive Officer of Misonix. "Pat has been an integral member of ConMed's executive team and his leadership expert

    5/14/21 8:30:00 AM ET
    $MSON
    Medical Specialities
    Capital Goods

    $MSON
    Financials

    Live finance-specific insights

    View All

    Misonix Reports Fourth Quarter and Fiscal Year 2021 Financial Results

    FARMINGDALE, N.Y., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Misonix, Inc. (NASDAQ:MSON) ("Misonix" or the "Company"), a provider of minimally invasive therapeutic ultrasonic medical devices and regenerative products that enhance clinical outcomes, today reported unaudited financial results for the fiscal 2021 fourth quarter and full fiscal year ended June 30, 2021 as summarized below:  Three Months Ended Years Ended  June 30, June 30,   2021   2020   2021  2020          Revenue$19,685,141  $13,713,231  $74,024,073 $62,483,651  Gross profit$14,075,377  $9,432,383  $52,636,255 $43,709,483  Gross profit percentage 71.5%  68.8%  71.1% 70.0% Pretax loss$(4,341,201) $(8,495,994) $(14,341,254)$(21,91

    9/2/21 4:01:00 PM ET
    $BVS
    $MSON
    Medical/Dental Instruments
    Health Care
    Medical Specialities
    Capital Goods

    Bioventus and Misonix Announce Definitive Agreement for Bioventus to Acquire Misonix

    Significantly Expands TAM and Adds Considerable Scale and Scope in Spine and Lower ExtremityEnhances Surgical Solutions Vertical by Adding Minimally Invasive Ultrasonic Technologies That Improve Clinical OutcomesDeepens Restorative Therapies Vertical by Adding Regenerative Medicine Wound ProductsBioventus and Misonix Management to Host Joint Conference Call Today at 4:30 p.m. Eastern Time DURHAM, N.C. and FARMINGDALE, N.Y., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus"), a global leader in innovations for active healing, and Misonix, Inc. (NASDAQ:MSON) ("Misonix"), a provider of minimally invasive therapeutic ultrasonic technologies and regenerative medicine

    7/29/21 4:05:00 PM ET
    $MSON
    $BVS
    Medical Specialities
    Capital Goods
    Medical/Dental Instruments
    Health Care

    Bioventus Inc. Reports Preliminary Second Quarter Net Sales; Updates Full-Year 2021 Net Sales Guidance

    DURHAM, N.C., July 29, 2021 (GLOBE NEWSWIRE) -- Bioventus Inc. (NASDAQ:BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today reported preliminary financial results for the three months ended July 3, 2021. Preliminary Second Quarter Net Sales: Net Sales of $108 million to $110 million represents 86.2% to 89.7% year-over-year growth and comprises: Net sales from legacy Bioventus Inc. of $96.5 million to $98.0 million, representing organic year-over-year revenue growth* of 66.4% to 69.0%, andNet sales from the acquisition of Bioness Inc. of $11.5 million to $12.0 million. Updated Full-Year 2021 Net Sales Guidance: For the twelve

    7/29/21 4:00:00 PM ET
    $MSON
    $BVS
    Medical Specialities
    Capital Goods
    Medical/Dental Instruments
    Health Care

    $MSON
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - MISONIX INC (0000880432) (Subject)

    2/16/21 4:01:08 PM ET
    $MSON
    Medical Specialities
    Capital Goods

    SEC Form SC 13G/A filed

    SC 13G/A - MISONIX INC (0000880432) (Subject)

    2/5/21 4:48:17 PM ET
    $MSON
    Medical Specialities
    Capital Goods